View all services

Mergers & Acquisitions

BridgeBio Pharma Acquires 36.35% of Eidos Therapeutics Shares

BridgeBio Pharma (Nasdaq: BBIO), a genetic-disease biotechnology company, is acquiring the remaining 36.35% of shares outstanding in Eidos Therapeutics (Nasdaq: EIDX), a specialized clinical-stage biotechnology company, for $1.03 billion.

Morrow Sodali acted as the proxy solicitor for the bidder in this transaction.

Find more information here.

For further inquiries
Contact us
Contact us

Please complete this form to be contacted by a Morrow Sodali representative.